Published in Br J Cancer on July 01, 1998
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
Epidermal growth factor receptor and bladder cancer. Postgrad Med J (2002) 1.02
CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol (2011) 1.01
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer (2004) 0.96
Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med (2011) 0.94
Matrix Metalloproteinases and Bladder Cancer: What is New? ISRN Urol (2012) 0.85
Pathobiology and chemoprevention of bladder cancer. J Oncol (2011) 0.84
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours. Br J Cancer (2007) 0.77
Bladder carcinoma data with clinical risk factors and molecular markers: a cluster analysis. Biomed Res Int (2015) 0.77
Epidermal growth factor receptor expression in canine transitional cell carcinoma. J Vet Med Sci (2014) 0.77
Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer. J Can Res Updates (2012) 0.76
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Genomic sequencing. Proc Natl Acad Sci U S A (1984) 92.36
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet (1990) 5.65
12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region. Mol Cell Biol (1987) 4.86
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med (1996) 2.42
The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol (1997) 2.07
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res (1993) 1.97
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem (1996) 1.92
Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol (1996) 1.89
Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer (1994) 1.55
Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev (1990) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res (1993) 1.45
Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer (1996) 1.25
Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C. Mol Cell Biol (1990) 1.22
Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg (1994) 1.19
Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer (1992) 1.15
High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res (1996) 1.05
Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry (1994) 1.00
Complex roles of matrix metalloproteinases in tumor progression. Curr Top Microbiol Immunol (1996) 1.00
Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol (1996) 0.96
Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer (1996) 0.95
Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev (1993) 0.92
Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells. Br J Cancer (1991) 0.91
Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer (1996) 0.87
Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. Br J Cancer (1994) 0.86
Epidermal growth factor in urine from the patients with urothelial tumors. Urol Int (1992) 0.80
Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients. Int J Urol (1994) 0.78
[Gene expressions of type IV collagenase and tissue inhibitor of metalloproteinases (TIMP) in human bladder cancers]. Nihon Hinyokika Gakkai Zasshi (1993) 0.78
Vitamin C exhibits pro-oxidant properties. Nature (1998) 3.22
Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis (1987) 2.48
Hypoxic-reperfusion injury in the inflamed human joint. Lancet (1989) 2.11
P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiat Oncol Biol Phys (1996) 2.06
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta (2002) 1.98
Quality assessment of genetic markers used for therapy stratification. J Clin Oncol (2003) 1.92
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 1.91
Free-radical oxidation (peroxidation) products in serum and synovial fluid in rheumatoid arthritis. J Rheumatol (1981) 1.86
Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet (1987) 1.69
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res (2001) 1.52
Self-perpetuating mechanisms of immunoglobulin G aggregation in rheumatoid inflammation. J Clin Invest (1985) 1.51
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
p53 and p53-regulated genes in bladder cancer. Br J Urol (1998) 1.46
Is chronic synovitis an example of reperfusion injury? Ann Rheum Dis (1986) 1.45
The cataract national data set electronic multi-centre audit of 55,567 operations: case-mix adjusted surgeon's outcomes for posterior capsule rupture. Eye (Lond) (2011) 1.44
Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer (2001) 1.43
Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis (1985) 1.41
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets (2007) 1.23
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int (2000) 1.21
Cerebral and ocular toxicity induced by desferrioxamine. Q J Med (1985) 1.21
Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer (2005) 1.19
Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology (1992) 1.18
Testicular prostheses: a new technique for insertion. BJU Int (2004) 1.17
Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis (2011) 1.17
Domperidone or metoclopramide in preventing chemotherapeutically induced nausea and vomiting. Br Med J (1979) 1.14
Free radicals and antioxidant systems in health and disease. Br J Hosp Med (1990) 1.14
The Cataract National Dataset electronic multi-centre audit of 55,567 operations: risk indicators for monocular visual acuity outcomes. Eye (Lond) (2012) 1.14
Caveolin-1 expression is associated with high-grade bladder cancer. Urology (2001) 1.13
Measurements using the alkaline comet assay predict bladder cancer cell radiosensitivity. Br J Cancer (2003) 1.11
Fluorescent lipid-peroxidation products in synovial fluid. Clin Sci (Lond) (1979) 1.11
The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res (2001) 1.11
Urinary 8-oxo-2'-deoxyguanosine--source, significance and supplements. Free Radic Res (2000) 1.11
The behaviour of caeruloplasmin in stored human extracellular fluids in relation to ferroxidase II activity, lipid peroxidation and phenanthroline-detectable copper. Biochem J (1985) 1.11
Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma. Genes Chromosomes Cancer (2001) 1.10
Intraoperative complications of cataract surgery in the very old. Br J Ophthalmol (2006) 1.10
p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol (2001) 1.10
Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. Med Pediatr Oncol (2001) 1.08
Free radicals in biological systems--a review orientated to inflammatory processes. Br Med Bull (1987) 1.07
Free radical oxidation (peroxidation)products in plasma in normal and abnormal pregnancy. Ann Clin Biochem (1981) 1.07
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene (2011) 1.05
Increased diene conjugates in diabetic subjects with microangiopathy. Diabet Med (1987) 1.04
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer (1996) 1.03
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene (2011) 1.02
The effects of vitamin C supplementation on protein oxidation in healthy volunteers. Biochem Biophys Res Commun (2000) 1.02
Molecular and cellular effects of ultraviolet light-induced genotoxicity. Crit Rev Clin Lab Sci (1998) 1.02
Epidermal growth factor receptor and bladder cancer. Postgrad Med J (2002) 1.02
The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract (1989) 1.01
Histological profile of tumours from MYCN transgenic mice. J Clin Pathol (2008) 1.01
The role of the tumour suppressor p33 ING1b in human neoplasia. J Clin Pathol (2003) 1.01
Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation. Diabetologia (1991) 1.00
Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res (1998) 0.99
Non-caeruloplasmin-bound copper ('phenanthroline copper') is not detectable in fresh serum or synovial fluid from patients with rheumatoid arthritis. Biochem J (1987) 0.98
Anaphylactic reaction to intraurethral chlorhexidine: sensitisation following previous repeated uneventful administration. Ann R Coll Surg Engl (2013) 0.98
Fluorescence changes in human gamma-globulin induced by free-radical activity. Biochim Biophys Acta (1983) 0.98
Rapid lupus autoantigen relocalization and reactive oxygen species accumulation following ultraviolet irradiation of human keratinocytes. Rheumatology (Oxford) (2000) 0.98
The role of special cutting equipment and corporeal aspiration in the treatment of penile incarceration with a barbell retaining collar. J Urol (2004) 0.97
Oxidative damage to DNA in patients with cystic fibrosis. Free Radic Biol Med (1995) 0.97
Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage? Br J Ophthalmol (1989) 0.96
Induction and excretion of ultraviolet-induced 8-oxo-2'-deoxyguanosine and thymine dimers in vivo: implications for PUVA. J Invest Dermatol (2001) 0.96
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer (2004) 0.96
Downregulation of nuclear expression of the p33(ING1b) inhibitor of growth protein in invasive carcinoma of the breast. J Clin Pathol (2003) 0.96
The expression of functional MSH receptors on cultured human melanocytes. Arch Dermatol Res (1992) 0.96
Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer (2001) 0.94
Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. Cancer Res (1992) 0.93
Reactive oxygen species selectively deplete normal T lymphocytes via a hydroxyl radical dependent mechanism. Scand J Immunol (1987) 0.93
Endothelial cell cytotoxicity in inflammatory vascular diseases--the possible role of oxidised lipoproteins. Ann Rheum Dis (1985) 0.92
Novel repair action of vitamin C upon in vivo oxidative DNA damage. FEBS Lett (1998) 0.92
Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group. Br J Cancer (2000) 0.92
Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet Med (1994) 0.92
Chain breaking antioxidant status in rheumatoid arthritis: clinical and laboratory correlates. Ann Rheum Dis (1991) 0.92
Reactive oxygen species modify human DNA, eliciting a more discriminating antigen for the diagnosis of systemic lupus erythematosus. Clin Exp Immunol (1990) 0.91
Ascorbic acid in the 21st century - more than a simple antioxidant. Environ Toxicol Pharmacol (2001) 0.91
Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol (2002) 0.91
Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res (1987) 0.91
Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells. Br J Cancer (1991) 0.91
Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res (2001) 0.90
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer (1998) 0.90
Tanagho bladder neck reconstruction in the treatment of adult incontinence. J Urol (1995) 0.90
Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet (1987) 0.90
The effects of oxygen free radicals on the carbohydrate moiety of IgG. FEBS Lett (1989) 0.90
Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int (2003) 0.89
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin Cancer Res (1999) 0.89
Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. Br J Urol (1994) 0.89
Effect of membrane fatty acid changes on the radiation sensitivity of human lymphoid cells. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.88
The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma. Gene (2003) 0.88
In vitro screening of iron chelators using models of free radical damage. Free Radic Res Commun (1986) 0.88
Reactive oxygen species induce antigenic changes in DNA. FEBS Lett (1989) 0.88
Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology (2002) 0.88
erbB receptor expression patterns in human bladder cancer. Urology (2005) 0.88
Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells. Eur J Cancer (1996) 0.87
A possible role for ferritin during inflammation. Free Radic Res Commun (1985) 0.87
Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer (1997) 0.87
Reactive oxygen species damage to DNA and its role in systemic lupus erythematosus. Mol Aspects Med (1991) 0.86